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Gefitinib versus chemotherapy as first-line treatment in elder 
patients with advanced non-small-cell lung cancer 
Zhang, Xiao-Tong; Li, Long-Yun; Wang, Men-Zhao; Zhang, Li;  
Zhong, Wei
Peking Uion Medical College Hospital & Chinese Academy of Medical 
Sciences, Beijing, China
Background: Elder patients with non-small cell lung cancer (NSCLC) 
have been habitually underrepresented in clinical trails. Retrospective 
analysis have shown similar therapeutic outcome of platinum-based 
combined chemotherapy for ﬁt elderly, albeit more toxicity compared 
with younger counterparts. Geﬁtinib, an oral EGFR-TKI was generally 
well tolerated with clinically meaningful anti-tumor activity in previ-
ously treated patients as well as chemo-na&iuml;ve patients. The aim 
of the study was to retrospectively evaluate the toxicity, efﬁcacy and 
survival of geﬁtinib versus platinum-based combined chemotherapy 
as ﬁrst-line treatment for a series of Chinese patients aged 70 and over 
with advanced NSCLC. 
Methods: from January 2002 to December 2005, 38 patients received 
chemotherapy (17 of Novelbine, 8 of Gemcitabine, 7 of taxol and 7 of 
taxotere, all of which combined with cisplatin or carboplatin) and 17 
patients received geﬁtinib 250mg once daily as ﬁrst line treatment. 
Results: Of the 38 patients who received chemotherapy, the median 
age was 73.3 years old (70-80) with 68.4% male, 73.7% adenocar-
cinoma and 78.9% patients were in stage 4. The PS of all patients 
was 0-1. Of the 17 patients who received geﬁtinib, the median age 
was 76.9 years old (70-85) with 58.8% male, 64.7% adenocarcinoma 
and 82.4% patients were in stage 4. The PS of 6 patients was over 2. 
The most frequently reported adverse events for chemotherapy group 
were neutropenia (92.1%) and thrombocytopenia(73.7%). Grade 3/4 
neutropenia was 21.1% and four patients had nertropenia febril. Grade 
3/4 thrombocytopenia was 10.5% and 2 patients need blood transfu-
sion. Other grade 3/4 adverse effects included 3 cases of vomiting and 
one case of cardiac arrhythmia. 4 patients withdrew the chemotherapy 
due to side effects. The most frequently reported adverse events for 
geﬁtinib group were skin disorders (70.6%) and diarrhea (35.3%). The 
majority of these events were mild with grade 1 to grade 2. One patient 
was hospitalization due to grade 3 diarrhea and recovered without drug 
administration disruption. Other adverse events included 2 cases of 
nausea, 1 case of oral ulcer and 1 case of elevation in hepatic enzymes. 
No patient withdrew due to adverse effect. The partial response and 
disease control rate were 21.1% and 78.9% for chemotherapy group 
versus 17.6% and 68.8% for geﬁtinib group. The median progress free 
survival and overall survival time were 4.93 ± 0.747 months (95% CI: 
3.465, 7.395) and 13.882 ± 0.718 months (95% CI: 12.892, 20.708) 
for chemotherapy group versus 6.4 ± 1.852 months (95%CI: 2.770, 
10.030) and 15.882 ± 2.029 months (95%CI: 13.654, 20.505). The one-
year survival was 52.6% in chemotherapy group versus 47.1% in geﬁ-
tinib group. There is no statistical signiﬁcance between the two groups 
for efﬁcacy, progress free survival time and overall survival time. 
Conclusion: Platinum-based combined chemotherapy was well toler-
ated and provides signiﬁcant anti-tumor activity in elder patients. 
Geﬁtinib as ﬁrst-line treatment provides similar clinical beneﬁt with 
less toxicity for the elder NSCLC patients. 
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A phase II trial of pemetrexed(p) in patients (pts) with performance 
status (PS) 2 and 3 as 1st- and 2nd- line treatment for advanced 
non-small-cell lung cancer (NSCLC)
Zinner, Ralph G. Fossella, Frank V. Kies, Merrill Herbst, Roy S. Lu, 
Charles Johnson, Faye Price, Justina Cleeland, Charles Wang, Shirley 
UT MD Anderson Cancer Center, Houston, TX, USA
P (Alimta) is approved as 2nd-line therapy in pts with advanced 
NSCLC. In a phase III trial comparing P with docetaxel (D), median 
survival was 8.3 mos (P) vs 7.9 mos (D); P had a more favorable safety 
proﬁle than D (Hanna, 2004). There are few data on pts with PS 3, and 
ASCO 2003 guidelines recommend that chemotherapy be reserved for 
pts with PS 0, 1 and possibly 2. Since P is well tolerated, PS3 pts may 
tolerate and beneﬁt from it. In this trial, we treated 20 pts with stage 
IIIb/IV NSCLC and PS 2 or 3, who were chemo-naive or had received 
1 prior regimen. Pts received P 500mg/m2 IV D1 Q 3 wks. All pts 
received folic acid, vitamin B12 and dexamethasone prophylaxis. Serial 
blood samples were obtained to monitor inﬂammatory cytokines, and 
symptoms were monitored using the validated MDASI instrument. All 
pts were assessable for toxicity-symptoms, and 17 pts were evaluable 
for response (assessed after 1st cycle). Pt characteristics: 8 pts were PS 
3 (4/8 1st line) and 12 pts were PS 2 (6/12 1st line). Median age was 
69 for PS3 and 68 for PS2. 5/8 PS3 pts and 6/12 PS2 pts were men. 
2/8 PS3 pts and 4/12 PS2 pts had stage IIIb. 4/8 PS3 pts and 6/12 PS2 
pts were chemo-naïve. Grade 3-4 toxicities for PS3/PS2 cohorts were: 
neutropenia 0/1 pt, anemia 1/2, fatigue 2/0, pneumonia 1/1, hypoten-
sion 1/1, neutropenic fever 0/1, atrial ﬁbrillation 1/1. Response rates 
(RR) in PS3 pts were minor response (MR) 1/8, stable disease (SD) 
5/8, progressive disease (PD) 2/8; RR in PS2 pts were partial response 
(PR) 1/12, MR 2/12, SD 3/12, PD 3/12, inevaluable 3/12. RR by line 
of therapy: 1st line 6/10 SD, 2/10 PD, 2/10 inevaluable, and 2nd line, 
1/10 PR, 2/10 MR, 3/10 SD, 3/10 PD, and 1/10 inevaluable. Reasons 
for PS3 pts coming off study were progression (4/8), constitutional 
toxicity (3/8), fatal pulmonary emboli (1/8); PS2 pts came off study 
due to progression (5/12), constitutional toxicity (2/12), and pneumonia 
(1/12). 4/12 PS2 pts are still on study. These preliminary data suggest 
that single-agent P is well-tolerated and has a promising RR in poor PS 
pts. Total planned accrual is 30 PS3 and 45 PS2 pts. Survival, symp-
tom, and cytokine data will be presented.
NSCLC: Radiation
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Utility of SPECT for metabolic and functional lung imaging in 
radiation therapy treatment planning for lung cancer
Agrawal, Sushma; Kheruka, Subhash; Das, Maria; Raj, Karthik; Lal, 
Punita; Gambhir, Sanjay 
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 
India
Background: Conformal radiotherapy of lung tumors relies on ana-
tomic imaging with CT scan to deﬁne both targets and critical structures, 
but has its drawbacks in differentiating atelectasis from tumor. Also, it 
may not represent the metabolic tumor volume and functional lung vol-
ume. We attempted to evaluate the utility of SPECT to gain information 
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regarding metabolic tumor volume as well as functional lung volume 
with the intent to design the beam portal for sparing functional lung. 
Patients and Methods: Nine patients of lung cancer suitable for 
radiotherapy had CT scan, MIBI (Sestamibi) SPECT and MAA 
(Macro-Aggregated Albumin) SPECT scans with ﬁducial markers and 
accurately co-registered using statistical parametric mapping software. 
These registered images were transferred into the planning system in 
which MIBI-SPECT images guided the target volume delineation and 
MAA-SPECT scans were used to deﬁne volume of perfused ‘function-
ing’ lung. When feasible, the design of the beam portal was placed 
attempting for a conformal approach. The gross tumor volume (GTV) 
of CT and MIBI, whole lung (WL) and functional lung (FL) volumes 
were calculated. The volume of lung receiving more than 20 Gy (V20) 
and mean lung dose (MLD) for WL and FL were also calculated. 
Results: MIBI and perfusion images was co-registered with radiother-
apy planning CT scans for delineation of target and functional lung. In 
comparison to the CT deﬁned target volumes, the MIBI deﬁned target 
volume were smaller in 4, larger in 1, similar in 2 and no appreciable 
uptake in 2 patients (these patients had also received prior chemo-
therapy). Perfusion SPECT revealed the ipsilateral lung completely non 
functional (same side as tumor) in 3 patients and so the functional lung 
was spared. In the other 6 patients with perfusion defect in and around 
the tumor bearing region, an attempt was made for conformal approach 
to spare the functional lung. (1.ppt)
Conclusion: SPECT images with MIBI and MAA were useful for map-
ping the metabolic target volume and functional lung. This enables to 
design beam portals for conformal avoidance of functional lung so as to 
reduce radiation morbidity.
P3-166 NSCLC: Radiation Posters, Wed, Sept 5 – Thurs, Sept 6 
Radiation oncologists’ attitudes on radiation volume and dose 
schedule when considering concurrent radiochemotherapy for 
stage III non-small cell lung cancer: A questionnaire study
Ahn, Yong Chan1 Park, Keunchil1 Wu, Hong Geun2 
1 Samsung Medical Center, Sungkyunkwan University School of Medi-
cine, Seoul, Korea 2 Seoul National University Hospital, Seoul, Korea 
A brief questionnaire was performed before starting a new prospective 
clinical trial employing concurrent radiochemotherapy (CRCT) for 
stage III non-small cell lung cancer (NSCLC) in 2005 to survey radia-
tion oncologists’ attitudes. A questionnaire consisted of 12 questions, 
which intended to evaluate career length, personal comfort degree on 
CRCT, preferred radiation dose schedules, and target volumes both in 
radiation alone and CRCT settings. This was circulated among 28 can-
didate radiation oncologists who would participate in the CRCT trial, 
and 17 responses were collected. 
Career lengths were longer than 5 years in six (35.3%), 2~5 years in 
seven (41.2%), and shorter than 2 years in four (23.5%). All respon-
dents agreed on the efﬁcacy of CRCT, however, 10 (58.8%) were not 
comfortable with CRCT regimen. There was minor tendency toward 
more conservative attitudes with respects to fractional dose, doses to 
primary, gross/elective lymph nodes, and most distal lymphatics to 
cover, mainly based on concerns of increased side effects, however, 
none was signiﬁcant. 
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Prophylactic cranial irradiation in non small cell lung cancer 
- should this be included in radical treatment
Azad, Gurdip; Ahmad, Shahreen; Stack, Bernadette 
Guy’s and St Thomas’ Hospitals NHS Trust, London, UK
Introduction: Brain metastases are three times less common in non-
small cell lung cancers (NSCLC) compared to small cell lung cancer 
(SCLC).Patients with SCLC are offered prophylactic cranial irradiation 
(PCI) as part of radical treatment in limited stage disease. PCI is not 
routinely offered in NSCLC, however as the treatments for NSCLC 
improve, especially with new targeted therapy agents in conjunction 
with chemotherapy and radiotherapy we are ﬁnding that patients are 
increasingly relapsing in the brain. Therefore the beneﬁcial role of pro-
phylactic cranial irradiation in patients with NSCLC is questioned and 
is the subject of a number of on-going trials. We present a review of our 
experience at Guys and St. Thomas’ Hospital to challenge this question.
Objective: A retrospective review of all patients with brain metastases 
from either small or non-small cell lung cancers over a period of six 
months to identify clinico-pathological markers that could categorize 
patients with NSCLC who would beneﬁt from prophylactic cranial 
irradiation. 
Methods: All patients with the diagnosis of lung cancer were identi-
ﬁed on electronic patient records, via the lung cancer nurses and the 
radiotherapy department between May and October 2006. The data was 
then collected by extraction from the case notes. The main outcome 
measures were occurrence of brain metastases and whether it was 
dependent on the initial stage of the disease.
Results: The total number of patients found was 75, out of which those 
with non small cell lung cancer were 58 (77.3%) and those with small 
cell lung cancer were 17 (22.6%). In the non small cell lung cancer 
group 8 out of the total of 58 (13.79%) developed brain metastases 
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